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ACE	 	 	 Angiotensin-converting	enzyme	
AV		 	 	 Atrioventricular	
	
β	 	 	 Beta	coefficient	
BMI		 	 	 Body	mass	index	
BNP		 	 	 Brain	natriuretic	peptide	
BP		 	 	 Blood	pressure	
bpm		 	 	 Beats	per	minute	
BSA		 	 	 Body	surface	area	
	
C		 	 	 Carboxy	
Ca		 	 	 Calcium	
CCL		 	 	 Collagen	cross-linking		
CITP		 	 	 Collagen	type	I	carboxy-terminal	telopeptide	
CMR		 	 	 Cardiac	magnetic	resonance		
CMR-FT		 	 Cardiac	magnetic	resonance	feature	tracking	
CVD		 	 	 Cardiovascular	disease		
CVF		 	 	 Collagen	volume	fraction		
	
DT		 	 	 Deceleration	time	
	
E/A	 	 	 Peak	early	/	Late	diastolic	ventricular	filling	velocity		
ECG		 	 	 Electrocardiography	
ECM		 	 	 Extracellular	matrix	
ECV		 	 	 Extracellular	volume	fraction		
EDV		 	 	 End-diastolic	volume	
EF		 	 	 Ejection	fraction		
eGRF		 	 	 Estimated	glomerular	filtration	rate		
viii 
 
ELISA		 	 	 Enzyme	linked	immunosorbent	assay	
ESC	 	 	 European	Society	of	Cardiology	
ESH		 	 	 European	Society	of	Hypertension	
ESV		 	 	 End-systolic	volume	
ET-1		 	 	 Endothelin-1	
	
HHD		 	 	 Hypertensive	heart	disease		
HR	 	 	 Heart	rate	
hs-Troponin	T		 High	sensitive	troponin	T		
HTN		 	 	 Hypertension		
	
IR-FISP		 	 Inversion	recovery	fast	imaging	with	steady	state	precession	
IV	 	 	 Interventricular	
	
LA		 	 	 Left	atrial	
LGE		 	 	 Late	gadolinium	enhancement	
LV		 	 	 Left	ventricular		
LVED	 	 	 Left	ventricular	end-diastolic	
LVES		 	 	 Left	ventricular	end-systolic		
LVH		 	 	 Left	ventricular	hypertrophy	
	
MAP		 	 	 Mean	arterial	pressure	
MMP		 	 	 Matrix	metalloproteinase		
MOLLI			 	 Modified	Look-Locker	Inversion-recovery		
	
N	 	 	 Amino	
n	 	 	 Number	
NPR	 	 	 Natriuretic	peptide	receptor	
NT-proBNP		 	 N-terminal	pro-brain	natriuretic	peptide	
	
p	 	 	 P-value	
PP	 	 	 Pulse	pressure	
ix 
 
PICP		 	 	 C-terminal	propeptide	of	procollagen	type	I		
PIIICP		 	 	 C-terminal	propeptide	of	procollagen	type	III	
PINP		 	 	 N-terminal	propeptide	of	procollagen	type	I		
PIIINP			 	 N-terminal	propeptide	of	procollagen	type	III	
PWV		 	 	 Carotid-femoral	pulse	wave	velocity		
	
r		 	 	 Pearson´s	product-moment	correlation	coefficient	
R2	 	 	 Coefficient	of	determination	
RAAS		 	 	 Renin-angiotensin-aldosterone	system	





SCMR		 	 	 Society	for	Cardiovascular	Magnetic	Resonance	
SD		 	 	 Standard	deviation	
shMOLLI		 	 Shortened	Modified	Look-Locker	Inversion	recovery	
SSFP		 	 	 Steady	state	fee	precession	
STE		 	 	 Speckle	tracking	echocardiography	
STIR		 	 	 Short-tau	inversion	recovery		
	
TDI		 	 	 Tissue	Doppler	imaging		
TGF	 	 	 Transforming	growth	factor	beta		
TIMP		 	 	 Tissue	inhibitor	of	metalloproteinase	
TTE		 	 	 Transthoracic	echocardiography	
	



























































































































































































































































































































































































The	disproportionate	growth	of	the	 left	ventricle	 involves	all	cardiac	cell	 types	and	 is	
mediated	 by	 a	 complex	 series	 of	 mechanical,	 neurohumoral,	 inflammatory,	 and	
oxidative	 stimuli	 (6).	 However,	 biomechanical	 stress	 related	 to	 HTN-mediated	






A	 change	 in	 ventricular	 form	 or	 mass	 inevitably	 induces	 an	 alteration	 in	 cardiac	










heart	 failure	and	 reduces	 subsequent	mortality	 (12,13).	Consequently,	 LVH	 is	 a	well-














Cardiac	 muscle	 cells	 respond	 to	 HTN-induced	 pressure	 overload	 with	 either	
hypertrophic	growth	or	anomalously	enhanced	apoptosis.	
	
Hypertrophy	 of	 cardiomyocytes	 together	 with	 functional	 systemic	 mechanisms	









in	 an	 increase	 in	 protein	 content	 and	 size	 of	 sarcomeres,	 the	main	 determinants	 of	








process	 including	 caspase-3	 and	 mitochondrial	 release	 of	 cytochrome-3	 deteriorate	
function	 and	 performance	 of	 cardiac	 cells	 (20).	 Furthermore,	 ongoing	 apoptosis	 of	







by	 fibroblasts,	 mainly	 collagen	 and	 proteoglycans.	 Collagen	 provides	 cardiac	 tensile	
strength,	actively	transduces	force	during	systole	and	is	the	main	determinant	of	cardiac	
relaxation	during	diastole.	The	myocardial	collagen	network	consists	of	3	components:	
the	 epimysium,	 collagen	 fibers	 surrounding	 the	 epicardium	 and	 endocardium;	 the	









are	 main	 determinants	 of	 the	 active	 relaxation	 process	 during	 diastole.	 Progressive	
accumulation	of	collagen	 fibers	with	altered	spatial	orientation	 impairs	cardiac	 filling	










First,	 an	 increased	 synthesis	 of	 collagens	 has	 been	 observed	 in	 fibrotic	 hearts.	
Procollagen	 is	 synthesized	 by	 fibroblasts	 in	 healthy	 individuals	 and	 additionally	 by	
transformed	fibroblast-like	cells	(myofibroblasts)	in	subjects	with	cardiac	disease	(23).	
The	transition	of	fibroblasts	to	myofibroblasts	is	mainly	regulated	by	hormones	of	the	







Second,	 the	 quality	 of	 collagens	 in	 the	 ECM	 is	 altered	 in	 the	 fibrotic	 state.	 Elevated	
extracellular	conversion	of	procollagen	into	microfibril-forming	collagen,	spontaneous	
microfibril	assembly	to	form	fibrils,	and	increased	cross-linking	of	fibrils	to	form	fibers	
contribute	 to	 the	 disruption	 of	 coordination	 of	 myocardial	 excitation-contraction	
coupling	in	systole	and	diastole	(24).	
Third,	 fiber	 degradation	 is	 decreased	 or	 unchanged	 in	 the	 hypertensive	 heart.	 The	
degradation	of	the	ECM	is	mainly	mediated	by	matrix	metalloproteinases	(MMPs)	and	









Intramyocardial	 blood	 vessels	 and	 the	 coronary	 vasculature	 endure	 structural	 and	
functional	 alterations	 in	 the	 hypertensive	 heart	 (26).	 Vascular	 smooth	 cells	 undergo	
hypertrophy	or	hyperplasia,	leading	to	changes	in	the	cellular	alignment	and	an	increase	
in	the	medial	thickness/lumen	ratio.	Capillary	rarefaction	and	disturbed	vascular	growth	




























Reactive	 interstitial	 fibrosis	 is	 characterized	 by	 an	 expansion	 of	 the	 myocardial	
interstitium	without	cardiomyocyte	 loss.	Diffuse	deposition	of	mature	collagen	in	the	
ECM	 and	 accumulation	 of	 fibrillary	 collagens	 in	 the	 cardiac	 vasculature	 are	 the	
histological	hallmarks	of	reactive	interstitial	fibrosis	(28).		
HTN	 and	 diabetes	 are	 the	 main	 conditions	 related	 to	 diffuse	 myocardial	 fibrosis.	
Activation	 of	 the	 sympathetic	 system	 and	 RAAS,	 overproduction	 of	 reactive	 oxygen	












(34,35).	 Importantly,	 diffuse	 reactive	 fibrosis	 can	 precede	 irreversible	 replacement	
fibrosis	(36).	It	is	therefore	important	from	a	clinical	point	of	view	to	detect	and	quantify	





Replacement	 fibrosis,	 also	 known	 as	 scarring	 fibrosis,	 is	 characterized	 by	 the	




cardiomyopathy,	 myocarditis	 and	 sarcoidosis	 are	 typically	 followed	 by	 focal	
replacement	 fibrosis.	 In	 contrast,	 systemic	diseases	 including	 chronic	 kidney	disease,	
systemic	inflammatory	disease	and	toxic	cardiomyopathy	are	related	to	diffuse	scarring	
fibrosis	(38,39).	Focal	replacement	fibrosis	after	myocardial	infarction	is	considered	an	







characterized	 by	 the	 deposition	 of	 insoluble	 proteins	 or	 glycosphingolipids	 (41).	 In	













The	 development	 of	 HHD	 is	 mediated	 by	 numerous	 hemodynamic	 and	 non-
hemodynamic	 factors.	 The	 presence	 of	 overt	 LVH	 can	 reliably	 be	 confirmed	 by	
electrocardiography	(ECG),	echocardiography	and	cardiac	magnetic	resonance	(CMR).	
However,	the	detection	of	subtle	cardiac	dysfunction	preceding	the	appearance	of	overt	
cardiac	 wall	 and	 mass	 increase	 is	 challenging.	 A	 growing	 number	 of	 molecular	
biomarkers	derived	from	the	complex	pathophysiological	mechanisms	resulting	in	HHD	
has	been	proposed	over	the	past	years.	The	potential	benefits	of	molecular	biomarkers	
include	 early	 detection	 of	 individuals	 prone	 to	 develop	 LVH,	 diagnosis	 of	 preclinical	








During	 synthesis	 and	 degradation	 of	 mature	 collagen	 fibers,	 propeptides	 and	
telopeptides	 are	 cleaved	 by	 endopeptidases	 and	 released	 into	 the	 bloodstream	 (46)	
(figure	 1.4).	 The	 propeptides,	 telopeptides	 and	 endopeptidases	 involved	 in	 collagen	









Figure	 1.4.	 Formation,	 structure	 and	 degradation	 of	 mature	 collagen.	 Cleavage	 of	








pro-α-collagen	 chains	 form	 a	 triple	 helix	 structure	 in	 the	 endoplasmatic	 reticulum,	


























synthesis	 (51).	 In	contrast,	 cleavage	of	 the	N-terminal	domain	of	procollagen	 type	 III	













Breakdown	 of	mature	 collagen	 fibers	 is	 accomplished	with	MMPs.	 The	MMP	 family	
contains	more	 than	25	 zinc-	and	calcium-dependent	enzymes,	mainly	 synthesised	by	
fibroblasts	and	leucocytes	(53).	Several	MMPs	are	expressed	in	the	heart.	MMP-1	is	a	
protease	 highly	 specific	 for	 collagen	 type	 I	 and	 III,	 and	 a	 key	 player	 in	 collagen	
fragmentation.	 MMP-1-mediated	 endopeptidase	 cleavage	 of	 mature	 collagen	 type	 I	
leads	 to	 a	 release	 of	 collagen	 type	 I	 carboxy-terminal	 telopeptide	 (CITP)	 into	 the	




The	 denatured	 collagen	 fragments	 are	metabolized	 by	MMPs	 known	 as	 gelatinases,	
namely	MMP-2	and	MMP-9.	Several	members	of	the	MMP	family	can	further	 induce	
activity	 of	 profibrotic	 proteins	 such	 as	 TGF-β	 and	 therefore	 interfere	 in	 the	 complex	
mechanisms	 of	 collagen	 turnover	 in	 the	 ECM.	 MMP	 activity	 is	 regulated	 at	 a	
































Myocardial	 wall	 stress	 is	 the	main	 stimulus	 for	 the	 synthesis	 and	 secretion	 of	 brain	
natriuretic	 peptide	 (BNP),	 a	 32-amino	 acid	 cardiac	 natriuretic	 peptide	 originally	
discovered	 in	porcine	brain	tissue	(60).	Ventricular	myocytes	and,	 to	a	 lesser	degree,	
fibroblasts	have	been	shown	to	be	the	major	source	of	BNP-related	peptides.	BNP	 is	









Ventricular	production	of	BNP	and	NT-proBNP	 is	upregulated	globally	 in	heart	 failure	
and	locally	in	the	area	adjacent	to	myocardial	ischemia	(62).	In	addition,	endocrine	and	
paracrine	activity	by	cytokines	and	neurohormones	have	been	shown	to	modulate	the	
synthesis	 and	 secretion	 of	 natriuretic-related	 peptides.	 The	 half-life	 of	 BNP	 and	NT-































Despite	myocardial	 ischemia	and	pressure	overload,	other	 conditions	have	 shown	 to	
lead	to	an	increase	in	circulating	troponin	T	including	increased	membrane	permeability	
(e.g.	in	sepsis),	end-stage	renal	disease,	excessive	training	routines	in	athletes,	and	non-
cardiac	 cardiovascular	 events	 (66–68).	 In	 addition,	 baseline	 levels	 of	 troponin	 T	 are	







assays	 has	 further	 shown	 that	 even	 very	 low	 levels	 of	 troponin	 T	 are	 independent	























lack	 sensitivity	 and	 specificity	 for	 the	 assessment	 of	 morphologic	 patterns	 in	 HHD,	
especially	 in	 young	 male	 subjects	 (73).	 Although	 ECG-derived	 assessment	 of	 LVH	
predicts	cardiovascular	events	in	hypertensives,	preclinical	alteration	of	cardiac	function	
cannot	 be	 reliably	 evaluated	with	 ECG	 (74).	 In	 addition,	 discrepancies	 regarding	 the	









M-mode	 echocardiography	 is	 a	 quick	 and	 simple	 procedure	 that	 provides	 highly	
accurate	 endocardial	 definition.	 Nevertheless,	 LV	mass	 assessment	 using	M-mode	 is	
performed	in	one	dimension	and	assumes	an	ellipsoid	shape	with	uniform	wall	thickness	
throughout	the	LV,	resulting	in	low	accuracy	(77).	2-dimensional	TTE	techniques	permit	



















dysfunction	 and	 heart	 failure	 with	 preserved	 ejection	 fraction,	 a	 clinical	 syndrome	
characterized	 by	 normal	 systolic	 function	 but	 clinical	 signs	 and	 symptoms	 of	 heart	
failure.	 Several	 TTE-derived	 methods	 are	 available	 for	 the	 estimation	 of	 diastolic	
dysfunction,	detectable	in	up	to	50%	of	hypertensive	patients	(14).	LV	mechanics	is	a	
determinant	of	left	atrial	(LA)	dimension	and	performance,	for	example,	LA	dilatation	






































layer	 is	 formed	by	fibers	oriented	 longitudinally	from	apex	to	base.	Consequently,	LV	
deformation	during	systole	determines	longitudinal	and	circumferential	shortening,	as	



















Direct	 strain	 acquisition	 techniques	 include	 CMR	 tagging,	 phase	 velocity	 mapping,	
strain-encoded	 imaging	 and	 displacement	 encoding	 with	 stimulated	 echoes.	 These	
techniques	require	dedicated	acquisition	time	in	the	scanner	and	cannot	be	applied	to	
routine	 CMR	 scans.	 In	 contrast,	 feature	 tracking	 technology	 is	 a	 post-processing	






short	 and	 long	 axis	 cines.	 Next,	 a	 dedicated	 feature	 tracking	 software	 is	 used	 to	
automatically	track	this	pattern	through	all	the	phases	of	the	cine	sequence.	Then,	the	






















search	areas	 for	 the	comparison	of	patterns,	as	a	 consequence,	 local	patterns	might	
become	 less	comparable	 (known	as	 image	de-correlation)	 (85).	CMR	feature	tracking	
















the	 deviation	 of	 reference	 values	 can	 be	 used	 to	 detect	 and	 quantify	 myocardial	
alterations	 including	 diffuse	 fibrosis.	 The	 measured	 T1	 values	 before	 and	 after	
administration	of	a	contrast	agent	are	represented	in	a	parametric	map	and	can	be	used	




acquisition	 times	 of	 around	 35-40	 seconds	 per	 image	 and	 tedious	 image	 post-
processing.	 Subsequently,	 the	 Modified	 Look-Locker	 Inversion-recovery	 (MOLLI)	
sequence	 was	 developed	 for	 the	 assessment	 of	 myocardial	 fibrosis	 (89).	 In	 this	
technique,	images	from	3	consecutive	inversion-recovery	experiments	are	merged	into	
1	data	set,	and	the	procedure	can	be	performed	during	a	single	breath-hold.	Nowadays,	
fast,	 accurate	 and	 reliable	 T1	mapping	 techniques	 are	 available,	 including	 shortened	
Modified	 Look-Locker	 Inversion	 recovery	 (shMOLLI)	 (90),	 which	 can	 be	 performed	
during	9	heartbeats	of	a	single	breath-hold,	Saturation	recovery	Single-Shot	Acquisition	

















Post-contrast	 T1	 is	 the	 spin-lattice	 relaxation	 time	 measured	 15	 minutes	 after	 the	




post-contrast	 T1	 values	 are	 determined	 by	 renal	 function,	 type	 and	 dosage	 of	 the	
contrast	 agent	 used,	 body	 composition,	 acquisition	 time	 and	 the	 cellular	 fraction	 of	
blood,	resulting	in	a	relatively	low	reproducibility.	
	
For	 the	quantification	of	myocardial	 fibrosis,	 the	partition	 coefficient	 can	be	derived	
from	native	and	post-contrast	T1	mapping.	The	myocardium	consists	of	the	intracellular	
compartment	 (cardiomyocytes	 and	other	 cell	 types),	 the	 ECM,	 and	 the	 intravascular	
compartment.	 Partition	 coefficient	 and	ECV	 comprise	 the	ECM	and	 the	 intravascular	
compartment,	and	it	is	generally	accepted	that	alterations	in	these	compartments	are	
mainly	mediated	by	changes	 in	 the	ECM	rather	 than	 the	 intravascular	compartment.	
Consequently,	 the	extension	of	 the	ECM	can	be	assessed	when	changes	 in	T1	 in	 the	


























For	 the	 assessment	 of	 ECV,	 the	 partition	 coefficient	 is	multiplied	 by	 the	 hematocrit	
factor	 (1-hematocrit)	 in	 order	 to	 adjust	 for	 the	 contrast	 agent	 plasma	 volume	 (88).	
Consequently,	ECV	is	independent	of	potentially	confounding	factors	that	might	have	an	
impact	 on	 the	measured	 values	 of	 post-contrast	 T1,	 like	 the	 rate	 of	 contrast	 agent	
clearance	from	blood	and	tissue.		
	
It	 is	 important	 to	 point	 out	 that	 both	 ECV	 and	 the	 partition	 coefficient	 reflect	 the	
expansion	 of	 the	 interstitial	 space,	 they	 are	 not	 a	 direct	measure	 of	 the	 amount	 of	
fibrotic	tissue	in	the	cardiac	wall.	Expansion	of	the	ECM	is	frequently,	but	not	exclusively,	
due	to	diffuse	fibrosis.	However,	in	absence	of	infiltrative	or	ischemic	cardiac	disease,	
ECV	 and	 the	 partition	 coefficient	 can	 be	 considered	 as	 imaging	 markers	 of	 diffuse	










on	 the	 measurement	 of	 brachial	 BP.	 Peripheral	 BP	 is	 an	 established	 predictor	 of	
cardiovascular	 risk,	 and	 BP-lowering	 treatment	 is	 followed	 by	 a	 reduction	 in	
cardiovascular	and	all-cause	morbidity	and	mortality	(97).	However,	over	the	past	years,	
interest	in	central	BP	and	carotid-femoral	pulse	wave	velocity	(PWV)	has	grown	owing	








PWV	 is	considered	 the	gold	standard	 for	 the	assessment	of	arterial	 stiffness	and	has	
been	found	to	be	an	independent	marker	of	cardiovascular	disease	both	in	the	high-risk	
and	in	the	general	populations.	Increasing	evidence	has	revealed	that	measurement	of	
PWV	 improves	 cardiovascular	 risk	 stratification	 and	 has	 a	 promising	 potential	 as	 a	
surrogate	 endpoint	 of	 cardiovascular	 disease.	 The	 current	 European	 Society	 of	
Hypertension	 (ESH)	and	European	Society	of	Cardiology	 (ESC)	guidelines	 recommend	
determining	PWV	for	risk	assessment	in	hypertension,	and	a	cut-off	value	for	‘high’	PWV	

























of	 cardiovascular	morbidity	 and	mortality,	 even	 at	 subclinical	 stages	 of	 disease.	 It	 is	














































Hypertensive	heart	 disease	 is	 characterized	by	 a	 disproportionate	 growth	of	 the	 left	
ventricle	 that	 involves	all	 cardiac	cell	 types.	Cardiac	magnetic	 resonance	 imaging	has	







The	 hypothesis	 of	 the	 present	 study	 is	 that	 cardiac	 magnetic	 resonance-derived	















• Investigate	 the	 relationship	between	CMR-assessed	myocardial	 strain,	 cardiac	






• Investigate	 the	 association	 between	 peripheral	 hemodynamics	 with	 CMR-
derived	 parameters	 of	 cardiac	 geometry,	 strain,	 fibrosis,	 and	 molecular	
biomarkers	of	fibrosis	
• Investigate	the	association	between	central	hemodynamics	and	arterial	stiffness	
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appropriate	 cuff	 according	 to	 the	 circumference	 of	 the	 non-dominant	 arm.	





them,	 additional	 measurements	 were	 performed.	 Patients	 were	 classified	 as	












Central	 BP	 and	 PWV	 were	 assessed	 using	 the	 SphygmoCor	 device	 (AtCor	 Medical,	
Australia)	as	previously	reported	(98).	Measurement	was	performed	in	a	quiet	room	and	






was	 reconstructed	 from	 the	 radial	 artery	 pressure	 waveforms	 using	 a	 generalized	
validated	transfer	function	(102)	(figure	3.1).	
	




























were	 checked	 against	 simultaneous	 measurement	 with	 a	 semiautomatic	 device	
(OMRON	M-6)	before	beginning	of	recording,	differences	between	devices	<	5	mmHg	
















Standard	12-lead	electrocardiograms	were	 recorded	by	 skilled	ECG	 technicians	at	25	
mm/s	 and	 1	 mV/cm	 according	 to	 standard	 American	 Heart	 Association	
recommendations	and	their	 results	were	 interpreted	by	2	physicians	 (103).	Sokolow-




















geometry,	 systolic	 function	 and	 diastolic	 function	 (figure	 3.5).	 M-Mode	




























surface	 coils	 and	 retrospective	 ECG	 triggering	 for	 capture	of	 the	 entire	 cardiac	 cycle	
including	diastole.	Balanced-SSFP	end-expiratory	breath-hold	cines	were	acquired	in	the	














also	 acquired	 in	 3	 short	 axis	 slices	 (basal,	 middle,	 apical	 levels)	 before	 contrast	
administration.	This	acquisition	was	repeated	in	the	same	orientations	15	minutes	after	
contrast	administration.	
Rest	 first	 pass	 myocardial	 perfusion	 images	 were	 acquired	 by	 using	 a	 saturation	
prepared	 gradient-echo	 sequence	 (TR/TE/matrix/spatial	 resolution	 of	




















variables	were	 quantified:	 LV	 end-diastolic	 (EDV)	 and	 end-systolic	 (ESV)	 volumes,	 LV	
mass,	 segmental	 LV	wall	 thickness,	 LA	dimension	and	volumes.	Regional	wall	motion	










For	 the	 assessment	 of	 myocardial	 strain,	 a	 surrogate	 for	 LV	 function,	 images	 were	







Figure	3.8.	 Strain	 assessment.	 From	 long-axis	 4-chamber	 cine	 image	 (A),	 longitudinal	






































3.9).	 Gadolinium-based	 contrast	 agents	 are	 distributed	 throughout	 the	 extracellular	
space	 and	 shorten	 T1	 relaxation	 times	 of	 the	myocardium	 proportional	 to	 the	 local	





















For	 the	 assessment	 of	 ECV,	 the	 cellular	 fraction	 of	 blood	 is	 required,	 which	 is	
represented	by	the	hematocrit.	ECV	was	calculated	using	the	formula:	
	








individuals	 with	 structural	 cardiac	 disease	 other	 than	 LVH	 (e.	 g.	 infiltrative	 disease,	














Laboratory	 analyses	 were	 performed	 on	 blood	 samples	 obtained	 under	 fasting	
conditions	 after	 30	 minutes	 of	 supine	 rest.	 Plasma	 glucose	 and	 serum	 sodium,	
potassium,	 creatinine	 and	 lipoproteins	 were	 measured	 using	 standard	 enzymatic	
automated	methods.		














CITP	 was	 assessed	 using	 a	 quantitative	 enzyme	 immunoassay	 (Orion	 Diagnostica,	





















NT-proBNP	 was	 assessed	 using	 the	 Elecsys®	 proBNP	 II	 STAT	 assay,	 following	 the	





instructions	 of	 the	 manufacturer.	 The	 assay	 employs	 2	 monoclonal	 antibodies	





























variables	 with	 p	 <	 0.1	 for	 the	 observed	 relationships	 in	 univariate	 analysis	 as	 the	
independent	variables.	Model	2	further	contained	height,	weight,	heart	rate	and	mean	
24-hour	systolic	BP	among	the	independent	variables	in	order	to	control	for	parameters	
that	 are	 known	 determinants	 of	 vascular	 hemodynamics	 and	 cardiac	 function.	
Regression	models	with	statistically	significant	associations	in	model	2	are	presented	in	
tables.	Models	are	not	shown	for	variables	with	marginal	or	significant	association	 in	
univariate	 analysis	 but	 p	 >	 0.5	 for	 the	 same	 comparison	 in	 fully	 adjusted	 models.	
Regression	lines	and	scatter	plots	of	independently	associated	variables	were	plotted	in	
order	 to	 graphically	 visualize	 the	 relationship	 among	 variables	 of	 interest.	
Multicollinearity	was	checked	for	calculating	the	variance	inflation	factor	(VIF)	for	each	
regression	 model.	 The	 VIF	 is	 an	 index	 which	 measures	 how	 much	 variance	 of	 an	























































A	 total	 of	 49	 participants	was	 initially	 included	 into	 the	 present	 study.	 9	 individuals	
refused	 to	undergo	CMR	 for	personal	 reasons	after	 informed	consent	was	obtained,	



































Age,	ys	 50.5	±	5.5	 50.6	±	4.3	 50.1	±	4.3	
Gender,	male	 39	(85)	 30	(83)	 23	(79)	
Weight,	kg	 88.9	±	15.2	 89.4	±	15.8	 89.4	±	15.6	
Height,	cm	 171	±	9.6	 172.3	±	10	 172.4	±	10.8	
BMI,	kg/m2	 30.3	±	3.8	 30	±	3.9	 30	±	3.6	
Waist	
circumference,	cm	 103	±	11	 101.5	±	10.6	 101.4	±	9.2	
Smoking	status	 	   
 Current	 21	(45.6)	 16	(44.4)	 15	(51.7)	
	 Former	 13	(28.3)	 11	(30.6)	 8	(27.6)	
	 Never	 12	(26.1)	 9	(25)	 6	(20.7)	
Diabetes	mellitus	 13	(28.3)	 10	(27.8)	 8	(27.6)	
Dyslipidaemia	 36	(78.3)	 29	(80.6)	 23	(79.3)	









































































































































Table	 4.6	 shows	 the	 mean	 values	 and	 SD	 of	 CMR-derived	 data.	 Mean	 cardiac	 wall	











is	 generally	 accepted	 that	 mean	 longitudinal	 strain	 lower	 than	 -17	 %	 (i.	 e.,	 higher	
absolute	values	 than	 -17	%)	and	mean	circumferential	 strain	 lower	 than	 -20	%	 (i.	 e.,	






Normal	 reference	 ranges	 for	 ECV	 and	 partition	 coefficient	 are	 not	 definitively	
established.	In	a	multicentre	setting	using	3T	scanners,	normal	values	for	ECV	and	the	
partition	coefficient	were	defined	as	0.26%	±	0.04	and	0.44	±	0.07,	respectively	(115).	In	




























Molecular	 biomarkers	 of	 fibrosis	 were	 determined	 in	 48	 participants.	 3	 participants	
were	 excluded	 due	 to	 onset	 of	 nephropathy	 (n=1)	 or	 detection	 of	 structural	 cardiac	
disease	other	than	LVH	(n=2),	leaving	a	total	of	45	individuals	for	statistical	analysis.	A	
total	of	8	study	participants	showed	MMP-1	levels	below	the	analytical	detection	limit.	




















































































































































The	 relationship	 between	 parameters	 from	 vascular	 hemodynamics,	 CMR-derived	







































































































PWV	 as	 an	 established	 surrogate	 of	 arterial	 stiffness	 was	 significantly	 related	 to	 LV	
geometry:	 the	 higher	 the	 PWV,	 the	 lower	 the	 LV	 end-systolic	 volume.	 Furthermore,	
there	was	a	trend	to	higher	PWV	values	when	LV	wall	thickness	was	increased.	
	


































geometry	 	      
Interventricular	
septum,	mm	 0.18	 	     
Posterior	wall,	mm	 	 0.13	 	    
LV	mass,	g	 	  0.70**	 	   
LV	end-diastolic	
volume,	ml	 	   0.38*	 	  
LV	end-systolic	
volume,	ml	 	    0.45**	 	
LA	diameter,	mm	 		 		 		 		 		 0.51**	

















Table	 4.11.	 Pearson’s	 correlation	 coefficients	 among	 LV	 wall	 thickness	 and	 mass,	
myocardial	strain,	LA	function	and	biomarkers.	
		 IV	septum,	mm	 Posterior	wall,	mm	 LV	mass,	g	
Cardiac	function	(n=33)	 	   
Radial	strain,	%	 -0.11	 -0.21	 -0.28	
Circumferential	strain,	%	 -0.14	 0.03	 0.07	
Longitudinal	strain,	%	 0.03	 0.12	 0.16	
LA	total	emptying	volume,	ml	 -0.12	 -0.05	 0.31°	
LA	total	emptying	fraction,	%	 0.13	 -0.04	 -0.16	
Cardiac	fibrosis	(n=29)	 	   
Extracellular	volume	fraction,	%	 0.38°	 0.40*	 0.39*	
Partition	coefficient		 0.35°	 0.61**	 0.55**	
Biomarkers	(n=36)	 	   
PICP,	μg/L	 0.01	 0.05	 0.03	
PIIINP,	μg/L	 0.72	 0.22	 0.02	
MMP-1,	μg/L	 0.11	 0.24	 0.12	
CITP,	μg/L	 0.12	 0.19	 0.16	
CITP/MMP-1	 -0.15	 0.17	 -0.17	
NT-proBNP,	pg/ml	 0.10	 0.32°	 0.33°	
Hs-Troponin	T,	pg/ml	 0.51**	 0.53**	 0.73**	




















decrease	 in	 radial	 strain.	 In	 addition,	 LV	 end-diastolic	 volume	 showed	 a	 positive	
relationship	with	 cardiac	 fibrosis	 and	 hs-Troponin	 T,	 biomarker	 of	myocardial	 injury,	
whereas	no	association	with	circulating	biomarkers	of	fibrosis	was	found.	
	









Cardiac	function	(n=33)	 	   
Radial	strain,	%	 -0.04	 -0.69**	 -0.42*	
Circumferential	strain,	%	 0.12	 0.35*	 0.21	
Longitudinal	strain,	%	 0.23	 0.16	 0.18	
LA	total	emptying	volume,	ml	 0.42*	 0.35*	 0.63**	
LA	total	emptying	fraction,	%	 -0.03	 -0.09	 -0.12	
Cardiac	fibrosis	(n=29)	 	   
Extracellular	volume	fraction,	%	 0.48**	 0.27	 0.39*	
Partition	coefficient		 0.35°	 0.13	 0.25	
Biomarkers	(n=36)	 	   
PICP,	μg/L	 -0.08	 -0.03	 0.09	
PIIINP,	μg/L	 0.01	 -0.17	 -0.09	
MMP-1,	μg/L	 0.15	 0.10	 0.25	
CITP,	μg/L	 0.26	 0.03	 0.17	
CITP/MMP-1	 -0.07	 -0.08	 -0.17	
NT-proBNP,	pg/ml	 0.19	 0.07	 0.21	
Hs-Troponin	T,	pg/ml	 0.48**	 0.12	 0.39*	





Longitudinal	 strain	was	 related	 to	 cardiac	 fibrosis:	 the	 higher	 the	 values	 of	 ECV,	 the	
higher	the	values	of	longitudinal	strain.	In	other	words:	the	higher	the	degree	of	fibrosis,	
the	 greater	 the	 reduction	 in	 longitudinal	 strain	 (i.e.	 “more	 positive”	 values	 of	







Consequently,	 longitudinal	 strain	 was	 associated	 with	 CITP/MMP-1:	 the	 higher	
CITP/MMP-1,	the	greater	the	reduction	in	longitudinal	strain.	
	
Circumferential	 strain	was	not	 related	 to	cardiac	 fibrosis	assessed	by	CMR,	however,	














Cardiac	fibrosis	(n=29)	 	   
Extracellular	volume	fraction,	%	 -0.24	 0.18	 0.42*	
Partition	coefficient	 -0.17	 0.16	 0.22	
Biomarkers	(n=33)	 	   
PICP,	μg/L	 0.08	 -0.10	 0.13	
PIIINP,	μg/L	 0.16	 -0.19	 -0.08	
MMP-1,	μg/L	 0.23	 -0.28	 -0.33°	
CITP,	μg/L	 -0.28	 0.18	 0.42*	
CITP/MMP-1	 -0.29	 0.32°	 0.43*	
NT-proBNP,	pg/ml	 0.05	 -0.08	 0.09	
Hs-Troponin	T,	pg/ml	 -0.07	 0.04	 0.11	





















Cardiac	fibrosis	(n=29)	 	  
Extracellular	volume	fraction,	%	 0.09	 -0.01	
Partition	coefficient	 0.04	 -0.06	













CMR-derived	markers	 of	 cardiac	 fibrosis	 were	 not	 significantly	 related	 to	 circulating	
biomarkers	of	 fibrosis	 (table	4.15).	A	positive	 correlation	of	hs-Troponin	T	and	CMR-
assessed	 partition	 coefficient	 was	 found,	 however,	 the	 relationship	 between	
extracellular	volume	fraction	and	hs-Troponin	T	was	not	significant.	
	
Table	 4.15.	 Pearson’s	 correlation	 coefficients	 among	 cardiac	 fibrosis	 and	 circulating	
biomarkers.	
		 Extracellular	volume	fraction,	%	 Partition	coefficient	







































PICP,	μg/L	 X	 	      
PIIINP,	μg/L	 0.42**	 X	 	     
MMP-1,	μg/L	 0.22	 0.27°	 X	 	    
CITP,	μg/L	 -0.10	 -0.09	 -0.09	 X	 	   
CITP/MMP-1	 -0.23	 -0.27°	 -0.96**	 0.35*	 X	 	  
NTproBNP,	pg/ml	 -0.01	 -0.02	 0.08	 0.08	 -0.05	 X	 	
hsTroponin	T,	pg/ml	 -0.05	 0.27°	 0.16	 0.06	 -0.13	 0.34*	 X	



















Multiple	 regression	analysis	was	performed	 in	order	 to	assess	 the	 factors	associated	
with	 peripheral	 and	 central	 hemodynamics,	 CMR-derived	 parameters	 of	 myocardial	
strain,	 LA	 function,	 cardiac	 fibrosis,	 and	molecular	biomarkers	of	myocardial	 fibrosis,	









































	 R2=0.29	 	 R2=0.26	
Variable	 β	 p	 	 β	 p	
Gender,	female	 -0.03	 0.90	 	 -0.08	 0.77	
Age,	years	 0.06	 0.73	 	 -0.09	 0.61	
Height,	cm	 -0.10	 0.73	 	 -0.21	 0.46	
Weight,	kg	 0.05	 0.83	 	 -0.08	 0.74	
Heart	rate,	bpm	 0.14	 0.46	 	 0.23	 0.22	
24-h	systolic	BP,	mmHg	 -0.49	 0.017	 	   
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independent	 association	with	parameters	 of	 cardiac	 geometry,	myocardial	 strain,	 LA	
function	or	circulating	biomarkers	of	fibrosis	in	fully	adjusted	models.		
	










Among	 cardiac	 strain	 parameters,	 longitudinal	 strain,	 but	 not	 radial	 strain,	 was	




















100 120 140 160 180










		 R2=0.47	 		 R2=0.38	
Variable	 β	 p	 		 β	 p	
Gender,	female	 -0.10	 0.70	 	 -0.31	 0.29	
Age,	years	 -0.39	 0.06	 	 -0.19	 0.33	
Height,	cm	 0.21	 0.53	 	 -0.30	 0.37	
Weight,	kg	 -0.26	 0.41	 	 0.30	 0.29	
Heart	rate,	bpm	 -0.04	 0.84	 	 -0.09	 0.66	
24-h	systolic	BP,	mmHg	 -0.25	 0.19	 	 -0.05	 0.82	
LA	diameter,	cm	 0.75	 0.005	 	   
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Variable	 β	 p	 		 β	 p	
Gender,	female	 0.13	 0.67	 	 -0.01	 0.99	
Age,	years	 0.05	 0.79	 	 0.05	 0.80	
Heigt,	cm	 0.21	 0.53	 	 0.07	 0.85	
Weight,	kg	 0.05	 0.84	 	 0.13	 0.63	
Heart	rate,	bpm	 -0.1	 0.64	 	 -0.05	 0.81	
24-h	systolic	BP,	mmHg	 -0.22	 0.30	 	 -0.2	 0.35	
CITP,	μg/L	 0.46	 0.025	 	   










































Circumferential	 strain	 and	 CITP/	MMP-1	were	 significantly	 associated:	 A	 decrease	 in	
circumferential	 strain	 (i.e.,	 “more	 positive”	 values)	 was	 related	 to	 a	 higher	 ratio	 of	
CITP/MMP-1	 (table	4.22,	 figure	4.9).	 The	associations	between	circumferential	 strain	
and	levels	of	CITP	and	MMP-1	were	further	evaluated	in	order	to	gain	insight	into	the	
relationship	of	circumferential	strain	with	CITP/MMP-1.	Circulating	levels	of	MMP-1,	but	
not	 CITP,	were	 related	 to	 circumferential	 strain	 in	 fully	 adjusted	models	 (table	 4.22,	
figure	4.10).	
	































		 R2=0.32	 		 R2=0.37	
Variable	 β	 p	 		 β	 p	
Gender,	female	 -0.1	 0.71	 	 -0.11	 0.73	
Age,	years	 0.22	 0.24	 	 0.20	 0.27	
Heigt,	cm	 -0.43	 0.20	 	 -0.49	 0.15	
Weight,	kg	 0.39	 0.14	 	 0.44	 0.09	
Heart	rate,	bpm	 -0.35	 0.08	 	 -0.38	 0.05	
24-h	systolic	BP,	mmHg	 -0.36	 0.08	 	 -0.39	 0.05	
MMP-1,	μg/L	 -0.38	 0.047	 	   















































In	 fully	adjusted	models,	 LV	end-systolic	 volume	was	 inversely	associated	with	 radial	
























































respectively.	 The	 association	 between	 these	 biomarkers	with	 central	 and	 peripheral	
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		 R2=0.30	 		 R2=0.26	 		 R2=0.29	
Variable	 β	 p	 		 β	 p	 		 β	 p	
Gender,	female	 -0.12	 0.55	 	 0.49	 0.14	 	 0.29	 0.29	
Age,	years	 0.13	 0.40	 	 0.21	 0.27	 	 0.20	 0.27	
Height,	cm	 0.07	 0.75	 	 0.66	 0.06	 	 0.39	 0.19	
Weight,	kg	 -0.10	 0.63	 	 -0.29	 0.27	 	 -0.38	 0.14	
Heart	rate,	bpm	 -0.29	 0.07	 	 -0.25	 0.24	 	 -0.18	 0.32	
24-h	systolic	BP,	mmHg	 -0.04	 0.85	 	 -0.18	 -0.39	 	 -0.21	 0.32	
Pulse	wave	velocity,	m/s	 0.53	 0.013	 	      
Posterior	wall,	mm	 	   0.50	 0.051	 	   
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		 Model	A	(R2=0.45)	 		 Model	B	(R2=0.61)	
Variable	 β	 p	 		 β	 p	
Gender,	female	 -0.10	 0.70	 	 -0.13	 0.54	
Age,	years	 -0.02	 0.90	 	 0.09	 0.51	
Height,	cm	 0.47	 0.11	 	 -0.05	 0.81	
Weight,	kg	 -0.16	 0.50	 	 -0.27	 0.18	
Heart	rate,	bpm	 0.17	 0.31	 	 0.17	 0.22	
24-h	systolic	BP,	mmHg	 0.10	 0.58	 	 -0.05	 0.74	
LA	diameter,	mm	 0.47	 0.025	 	   

































































with	 impaired	cardiac	deformation	expressed	as	reduced	 longitudinal	strain,	which	 is	




Figure	 4.17.	 Schematic	 representation	 of	 the	 relationship	 between	 vascular	






































































The	 vast	 majority	 of	 study	 participants	 were	 male	 individuals	 (approximately	 85%).	
Physiological	 circulatory	 differences	 between	 men	 and	 women	 include	 estrogen-
mediated	vascular	relaxation,	shorter	length	of	the	arterial	tree,	faster	heart	rate	and	






All	 individuals	 included	 in	 the	present	 study	had	preserved	 renal	 function	defined	as	
estimated	 glomerular	 filtration	 rate	 (eGFR)	 >	 60	ml/min/m2.	 The	 adverse	 impact	 of	
kidney	disease	on	vascular	hemodynamics	and	cardiac	function	is	well	established	(126).	
In	addition,	the	reproducibility	and	standardization	of	serum	or	plasma	assays	used	for	
the	 assessment	 of	 molecular	 biomarker	 is	 determined	 by	 renal	 function	 (127).	 It	 is	
therefore	desirable	to	exclude	individuals	with	renal	dysfunction	when	the	relationship	
between	molecular	biomarkers	and	cardiovascular	mechanics	is	investigated.	
Large	 epidemiological	 studies	 have	 shown	 that	 HTN	 is	 frequently	 associated	 with	
metabolic	syndrome-related	comorbidities,	including	diabetes,	dyslipidemia	and	obesity	
(128–130).	Moreover,	the	onset	or	progression	of	one	of	these	conditions	confers	an	
increase	 in	 risk	 for	 the	 development	 or	 progression	 of	 the	 others	 (131–134).	










the	 present	 treatment	 recommendations	 of	 the	 ESH,	 which	 favors	 inhibitors	 of	 the	
renin-angiotensin	and	calcium	channel	blockers	as	first-line	treatments	(101).	However,	
BP	control	was	poor	in	the	present	study.	The	prevalence	of	LVH	is	directly	related	to	BP	




the	 morphological	 pattern	 or	 extension	 of	 LVH,	 particularly	 in	 children	 and	 young	








The	assessment	of	 cardiac	geometry	and	 function	 is	essential	 in	 the	management	of	
cardiac	disease.	Overt	alterations	 in	contractile	or	 relaxation	 function	can	 reliably	be	
detected	by	TTE,	which	 is	 the	 first-line	cardiac	 imaging	 technique	 in	 clinical	practice.	
However,	 the	 detection	 and	 quantification	 of	 subtle	 preclinical	 systolic	 or	 diastolic	
dysfunction	 is	 desirable	 in	 order	 to	 identify	 patients	 with	 elevated	 risk	 for	 adverse	
cardiovascular	 outcomes.	 CMR	 has	 become	 the	 gold	 standard	 for	 the	 non-invasive	
assessment	 of	 cardiac	 geometry	 and	 function,	 providing	 the	 highest	 accuracy	 and	
reproducibility	among	currently	available	imaging	techniques	(142,143).	In	the	present	
study,	 LV	mass	measured	 by	 CMR	 and	 by	 echocardiography	were	 highly	 correlated,	










TTE	 (83,145).	 For	 the	 assessment	 of	myocardial	 strain,	 CMR-FT	 and	 speckle	 tracking	
echocardiography	(STE)	are	the	most	important	imaging	techniques.	Both	methods	rely	
upon	 tissue	 tracking	 for	 the	assessment	of	 strain	parameters,	 and	numerous	 studies	
have	shown	a	good	agreement	between	both	techniques	(146–149).	However,	CMR-FT	
has	several	advantages	compared	to	STE	for	the	assessment	of	myocardial	strain.		
STE	requires	high	quality	 images	 for	post-processing	and	a	specific	 frame	rate	during	
image	acquisition	(150).	As	a	consequence,	routinely	acquired	echocardiography	studies	
are	 frequently	 not	 suitable	 for	 image	 post-processing,	 especially	 when	 the	 acoustic	
window	during	the	echocardiography	study	is	not	optimal.	The	signal-to-noise	ratio	of	
TTE-derived	 images	 is	 lower	 than	 in	 CMR-derived	 images	 and	 some	 myocardial	
segments	 cannot	 be	 adequately	 imaged	with	 STE.	 As	 a	 consequence,	 STE-measured	
values	need	to	be	averaged	in	order	to	assess	global	cardiac	strain.	In	addition,	STE	is	





seconds	 (152).	 However,	 CMR	 is	 not	 capable	 to	 distinguish	 features	 within	 the	
myocardium,	 probably	 due	 to	 the	 relatively	 large	 voxel	 dimensions	 and	 the	
homogeneous	water	content	and	tissue	properties	within	the	myocardium	(84).	Thus,	
CMR-FT	 is	most	 effective	 around	 endocardial	 and	 epicardial	 borders.	Moreover,	 the	
relatively	low	temporal	resolution	can	affect	tracking	if	the	search	window	is	big.	Finally,	
there	is	a	limitation	inherent	to	the	way	the	cine	sequence	is	produced.	Each	frame	of	
the	 cine	 loop	 is	 reconstructed	with	 information	 obtained	 during	 several	 heartbeats.	
Thus,	small	beat	 to	beat	differences	are	smoothed	out	and	this,	 in	combination	with	






has	 been	 observed	 for	 global	 strain	 measures	 (153).	 In	 ischemic	 heart	 disease,	 all	
myocardial	strain	parameters	have	been	found	to	be	altered	in	infarcted	territories.	In	




Global	 circumferential	 and	 longitudinal	 strain	 seem	 to	 be	 the	most	 consistent	 strain	
parameters	 regarding	 measurement	 agreement	 and	 reproducibility	 (83,159,160).	 In	
contrast,	 radial	 strain	 measures	 have	 been	 found	 to	 suffer	 from	 high	 variability,	
questioning	 the	 use	 of	 radial	 strain	 in	 clinical	 practice	 (86,113).	 An	 important	 issue	
regarding	measurement	 reproducibility	 is	 the	 growing	 availability	 of	 feature	 tracking	
software	 from	 several	 different	 vendors	 with	 independently	 developed	 software	
solutions	(160–162).	Consequently,	reference	values	of	strain	parameters	may	depend	




Despite	discrepancies	 regarding	measurement	of	 strain	parameters,	 reference	values	
for	LV	strain	parameters	have	been	published	(114,163).	CMR-FT	has	been	applied	for	









extracellular	 space.	 In	other	words,	 LGE	 is	 a	 “difference	 test”	 that	 requires	different	
















showed	 that	 shMOLLI	 and	MOLLI	 had	 higher	 precision	 for	 T1	mapping	 compared	 to	
SASHA	 and	 SAPPHIRE,	 whereas	 reproducibility	 was	 similar	 among	 these	 techniques	
(171).	In	contrast,	the	accuracy	of	shMOLLI	and	MOLLI	was	lower	compared	to	SASHA	
















However,	 a	 given	molecular	 biomarker	 actually	 reflects	myocardial	 fibrosis	when	 an	





cardiac	 fibrosis.	 The	 collagen	 turnover-derived	 propeptides	 and	 telopeptides	
investigated	 in	 the	 present	 study	 have	 all	 been	 validated	 against	 collagen	 volume	
fraction	(CVF),	the	percentage	of	total	myocardial	tissue	occupied	by	collagen	fibers.	CVF	
can	 be	 assessed	 in	 myocardial	 biopsy	 samples	 with	 collagen-specific	 staining	 using	
automated	image	analysis	systems	(180,181).	
	
PICP	 is	 released	during	the	extracellular	processing	of	procollagen	type	 I	 into	mature	
collagen	 type	 I	 by	 the	 enzyme	 procollagen	 type	 I	 carboxy-terminal	 proteinase	 and	
reflects	the	rate	of	synthesis	of	collagen	type	I	(46).	Serum	levels	of	circulating	PICP	levels	
have	 shown	 to	 be	 directly	 related	 to	 CVF	 in	 hypertensive	 patients	 with	 LVH.	
Furthermore,	PICP	levels	were	associated	with	CVF	in	individuals	with	HHD	and	heart	
failure.	 Interestingly,	 serum	 PICP	 levels	 changed	 in	 parallel	 with	 CVF	 in	 response	 to	
treatment	with	losartan	and	torasemide	in	subjects	with	HHD	(34,35).	PICP	also	showed	
predictive	value	for	clinical	outcomes	in	hypertensive	patients	with	heart	failure	(182).	
In	 patients	 with	 heart	 failure	 and	 reduced	 EF,	 PICP	 was	 directly	 and	 independently	





to	 CVF	 in	 patients	 with	 heart	 failure	 and	 dilated	 cardiomyopathy.	Moreover,	 serum	
PIIINP	changed	in	parallel	with	CVF	in	patients	with	severe	heart	failure	with	reduced	EF	




heart	 failure,	PIIINP	 levels	were	consistently	 related	to	mortality	and	adverse	cardiac	
outcomes	(52).		
CITP	is	released	by	endopeptidase	cleavage	by	MMPs	during	collagen	type	I	degradation	







(187).	 In	 contrast,	 lower	 levels	 of	 CITP	 were	 observed	 in	 individuals	 with	 dilated	
cardiomyopathy,	heart	failure	and	severe	fibrosis	compared	to	individuals	with	mild	to	






MMP-1	 is	 a	 calcium-dependent	 endopeptidase	 and	 the	 main	 determinant	 of	
extracellular	degradation	of	 collagen.	Activity	of	MMP-1	on	collagen	 type	 I	 results	 in	
cleavage	and	release	of	CITP	to	the	blood.	MMP-1	was	not	related	to	CVF	in	patients	
with	HHD,	however,	individuals	with	higher	levels	of	MMP-1	showed	reduced	levels	of	
perimysial	 and	 endomysial	 collagen	 in	 cardiac	 muscle	 connective	 tissue	 (189).	
Hypertensives	with	LVH	exhibited	 lower	 levels	of	MMP-1	compared	to	hypertensives	
with	normal	 LV	mass	 (190).	 In	 addition,	 serum	MMP-1	 levels	 predicted	 target	 organ	
damage,	cardiovascular	events	and	mortality	in	hypertensive	populations	(191,192).		
The	 ratio	 between	 CITP	 and	MMP-1	 has	 recently	 been	 proposed	 to	 reflect	 collagen	
cross-linking.	Available	evidence	on	the	prognostic	value	of	CITP/MMP-1	is	limited.	In	





In	 the	 present	 study,	 all	 continuous	 variables	 were	 tested	 for	 normality	 using	 the	
Shapiro-Wilk	test.	More	than	40	tests	are	available	to	determine	if	a	variable	is	normally	




Differences	 regarding	 normally-distributed	 clinical	 and	 biochemical	 characteristics	 of	










maximum	 number	 of	 independent	 variables	 that	 should	 be	 entered	 into	 regression	














the	 extension	 of	 fibrosis,	 the	 greater	 the	 cardiac	 dimension	 and	 the	 lower	 the	
























in	 LV	 wall	 thickness	 and	 stiffness,	 as	 a	 consequence,	 the	 end-diastolic	 muscle	 fiber	
length	is	reduced.	According	to	Frank-Starling´s	law,	a	reduction	in	muscle	fiber	length	








in	 correlation	models.	 These	 findings	 reflect	 the	morphological	 alterations	of	 cardiac	







mass	 index	 and	 the	 presence	 of	 LVH	 in	 univariate	 regression	 analysis	 including	 46	
hypertensive	 patients	 and	 50	 healthy	 controls,	 but	 did	 not	 report	 the	 results	 of	





TTE-derived	 criteria	 of	 LVH,	 the	 study	 is	 likely	 underpowered	 to	 detect	 significant	
associations	of	LV	mass	with	myocardial	fibrosis	when	covariates	are	controlled	for.		
	
Elevated	 systemic	 pressure	 is	 the	 main	 risk	 factor	 for	 an	 increase	 in	 LV	 mass,	 and	
subsequently,	diffuse	myocardial	fibrosis.	A	direct	relationship	between	CMR-assessed	
myocardial	 fibrosis	and	HTN-induced	pressure	overload	was	observed	 in	both	animal	
models	 and	 hypertensive	 patients	 (199,201).	 In	 addition,	 ECV	 has	 been	 found	 to	 be	
useful	for	the	determination	of	the	extension	of	LVH	in	hypertensives	(198).		
Peripheral	BP	measures	were	significantly	associated	with	LV	mass,	but	not	with	ECV	or	
the	 partition	 coefficient	 in	 the	 present	 study.	 In	 addition,	 no	 significant	 associations	
between	 central	 hemodynamics,	 cardiac	 geometry	 and	 myocardial	 fibrosis	 were	
observed.	BP	levels	failed	to	predict	ECV	in	hypertensives	with	LVH	in	a	previous	study	
(202)	However,	the	absence	of	a	significant	association	in	the	present	study	is	likely	due	
to	 the	 impact	of	BP	 treatment	 in	 the	 investigated	 cohort.	All	 individuals	were	under	
active	antihypertensive	treatment,	and	the	vast	majority	received	2	or	more	BP	lowering	
drugs.	Moreover,	 all	 patients	 received	 RAAS	 inhibitors,	 a	 drug	 class	 with	 effects	 on	
cardiac	 microstructure	 and	 vessel	 function	 independent	 of	 the	 BP	 lowering	 effect	
(203,204).	On	the	other	hand,	a	non-linear	relationship	between	myocardial	fibrosis	and	
systemic	 BP	 has	 been	 proposed.	 Upregulation	 of	 pro-fibrotic	 genetic	 pathways	 and	
excessive	sympathetic	activity	in	the	heart	independent	of	BP	levels	have	been	observed	
(205,206).	It	is	possible,	that	BP	levels	do	not	increase	in	parallel	with	LV	mass	in	order	
to	avoid	excessive	 increase	 in	afterload,	which	would	have	a	negative	 impact	on	 the	
already	 stressed	 LV	 mechanics.	 Further	 studies	 are	 needed	 to	 gain	 insight	 into	 the	
complex	relationship	between	vascular	hemodynamics	and	myocardial	fibrosis.	
	
CMR-derived	 myocardial	 strain	 has	 been	 extensively	 investigated	 in	 ischemic	 heart	
disease,	 idiopathic	 dilated	 cardiomyopathy,	 hypertrophic	 cardiomyopathy,	 valve	
stenosis,	 chemotherapy-induced	 cardiotoxicity,	 and	 for	 the	 evaluation	 of	 treatment	
response	 (82,86).	 In	 contrast,	 the	 role	 of	 CMR-FT	 in	 the	 quantification	 of	 preclinical	
alterations	of	cardiac	function	in	HHD	has	not	been	firmly	established	yet.		
In	 the	present	study,	myocardial	strain	parameters	showed	no	significant	association	





associated	 with	 TTE-measured	 LV	 mass	 in	 a	 study	 including	 320	 newly-diagnosed	
hypertensives	 and	 160	 controls	 (207).	 The	 participants	 of	 the	 present	 study	 were	
characterized	by	an	advanced	state	of	HDD	with	a	LVH	prevalence	of	100%,	therefore,	
the	study	may	be	underpowered	to	find	a	significant	association	of	LV	mass	with	strain.	
However,	 strain	 parameters	 were	 related	 to	 LV	 volumes,	 which	 depend	 on	 cardiac	
structure	and	functioning.	Radial	strain	was	inversely	related	to	LV	end-systolic	volume	
in	 fully	 adjusted	 regression	 models,	 and	 correlated	 negatively	 with	 LV	 end-diastolic	
volume.	Furthermore,	 circumferential	 strain	correlated	 inversely	with	LV	end-systolic	
volume.	 It	 is	 well	 known	 that	 LV	 chamber	 filling	 and	 myocardial	 shortening	 or	
lengthening	 are	 closely	 interrelated	 (208,209).	 A	 reduction	 in	 radial	 strain	 confers	 a	
decrease	 in	 radial	 thickening	 during	 the	 cardiac	 cycle,	 leading	 to	 a	 reduced	 inward	

















The	 exact	 interaction	 between	 vascular	 hemodynamics	 and	 strain	 as	 an	 indicator	 of	
early	 subclinic	 cardiac	 dysfunction	 is	 not	 fully	 understood.	 In	 the	 present	 study,	 the	
relatively	 low	number	of	 study	participants	 together	with	 the	high	prevalence	of	BP-













diastolic	 function	 and	 heart	 failure	 (217).	 Importantly,	 CITP	 was	 associated	 with	
impaired	 systolic	 function	 and	 adverse	 clinical	 outcomes	 in	 prospective	 studies	
(187,216).	Elevated	CITP	levels	further	predicted	cardiovascular	and	all-cause	mortality	
in	a	study	including	patients	with	heart	failure	and	impaired	LV	systolic	function	(184).	





with	 circulating	 levels	of	MMP-1:	 the	 lower	 the	 circumferential	 strain,	 the	 lower	 the	
levels	of	MMP-1.	 In	 accordance	with	 the	present	 finding,	 low	 levels	of	MMP-1	were	
associated	with	 systolic	dysfunction	defined	as	EF	≤	35	%	and	mortality	 in	260	heart	
failure	patients	 (218).	Low	levels	of	MMP-1	further	determined	functional	status	and	
prognosis	 in	 chronic	heart	 failure	patients	 (219).	 In	 contrast,	higher	 levels	of	MMP-1	















1	 in	 fully	 adjusted	 regression	models	 and	marginally	 related	 to	MMP-1	 in	 univariate	












CITP	 levels	 and	 a	 decrease	 in	 PICP	 levels	 was	 observed	 following	 treatment	 with	
losartan,	an	angiotensin	II	antagonist,	and	after	treatment	with	Ramipril,	an	angiotensin-
converting	enzyme	inhibitor,	in	combination	with	hydrochlorothiazide	or	canrenone	(a	
thiazide-type	 diuretic	 and	 an	 antagonist	 of	 aldosterone,	 respectively)	 (35,220).	
Treatment	with	losartan	also	lowered	PICP	levels	in	hypertensives	with	HHD	(221).	Díez	
et	 al	 observed	 a	 significant	 decrease	 in	 PICP	 and	 PIIINP	 levels	 after	 treatment	 with	


















Third,	molecular	biomarkers	of	 fibrosis	may	be	 released	 from	non-cardiac	 sources	of	
collagen	turnover,	 therefore,	 they	are	not	specific	 for	 the	myocardium.	For	example,	
molecular	biomarkers	of	fibrosis	have	been	used	in	the	assessment	of	liver	fibrosis	and	




and	 injury,	 respectively,	 were	 consistently	 associated	 with	 measures	 of	 cardiac	
geometry	and	LV	mass.	Numerous	studies	have	confirmed	a	direct	relationship	between	
NT-proBNP	 or	 BNP	 with	 LV	 structure	 and	 LV	 mass	 in	 hypertensives	 (230–234).	
Furthermore,	levels	of	NT-proBNP	were	predictors	of	cardiovascular	events	and	death	
























was	observed	 in	 a	prospective	 study	 including	heart	 failure	patients,	 suggesting	 that	
cardiac	 microinjury	 adversely	 affects	 biomarkers	 of	 collagen	 metabolism	 (116).	 The	
biological	processes	involved	in	tissue	repair	require	an	adequate	amount	and	quality	of	




In	 summary,	 CMR-derived	 strain	 analysis,	 T1	 mapping	 and	molecular	 biomarkers	 of	
fibrosis	 are	 interrelated	 and	 might	 be	 useful	 tools	 for	 the	 identification	 and	
characterization	 of	 preclinical	 cardiac	 dysfunction	 and	 diffuse	 myocardial	 fibrosis	 in	







allow	 recommending	 the	 routinely	 use	 of	 these	 techniques	 in	 clinical	 practice.	
Harmonization	of	measurement	methods	for	the	assessment	of	CMR-derived	strain	and	
ECV	 would	 be	 desirable	 for	 an	 adequate	 comparison	 of	 performance	 of	 these	
parameters	among	different	study	populations.	
Molecular	 biomarkers	 of	 fibrosis	 were	 related	 to	 strain	 but	 performed	 poorly	 as	
predictors	of	LV	wall	thickness,	LV	mass	or	CMR-derived	cardiac	fibrosis	in	the	present	
study.	Therefore,	 the	determination	of	 these	biomarkers	 should	 remain	 restricted	 to	
investigational	purpose	and	 is	not	suitable	 for	clinical	decision	making	under	present	
conditions.	 It	 is	 important	 to	 point	 out	 that	 a	 relatively	 small	 number	 of	 study	
participants	with	a	complete	dataset	was	available	for	statistical	analysis.	Moreover,	the	





ascertained.	 In	 future	 studies,	 the	 performance	 of	 strain	 imaging,	 T1	 mapping	 and	














































• CMR-assessed	 fibrosis	 showed	 significant	 associations	 with	 cardiac	 geometry	
and	myocardial	strain:	A	greater	extension	of	cardiac	fibrosis	was	related	to	an	




• Myocardial	 strain	 and	 LV	 volumes	 were	 directly	 related.	 Radial	 strain	 was	
independently	 and	 inversely	 associated	 with	 LV	 end-systolic	 volume,	 an	
established	surrogate	for	afterload	and	contractility.	
	





injury,	were	 directly	 related	 to	 LV	mass.	 NT-proBNP	 and	 hs-Troponin	 T	were	




identified	 with	 CMR	 imaging.	Myocardial	 fibrosis	 is	 associated	 with	 impaired	
cardiac	deformation	expressed	as	reduced	longitudinal	strain,	which	is	related	to	
molecular	 biomarkers	 of	 fibrosis.	 Moreover,	 changes	 in	 LV	 mass,	 LV	 wall	
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